Navigation Links
Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
Date:3/11/2008

iew of the short expected survival time of approximately six months in this patient population, it is promising that we have early GBM patients in these trials who have survived past the six-month timeframe, with one patient now surviving 15 months post-treatment."

The open-label Phase I dosing and dosimetry study at U.S. brain cancer centers is enrolling GBM patients with recurrent disease. Patients in this trial receive an initial imaging dose of Cotara before receiving the therapeutic dose. The study's main objectives are to confirm the maximum tolerated dose, to determine radiation dosimetry and to assess overall patient survival, progression-free survival and the proportion of patients alive at six months following Cotara administration. In the three GBM patients enrolled in the first cohort, Cotara was safe and well tolerated, with no dose-limiting toxicities. Patients have been followed post-treatment to determine overall survival, with the first treated patient currently surviving 15 months post-treatment and the last treated patient currently surviving four months post-treatment. Dosimetry analysis indicates that Cotara was concentrated only in the tumor in these patients, and not in other organs.

Mr. King added, "With enrollment of the second patient cohort underway, we welcome Dr. William Shapiro of the Barrow Neurological Institute as principal investigator of our newest dosimetry study clinical site. Dr. Shapiro successfully participated in earlier Cotara studies and we are delighted that his center is now participating in the Cotara dosimetry trial."

"We are pleased to join the dosing and dosimetry trial of Cotara for the treatment of recurrent GBM," said Dr. William Shapiro, director, neuro oncology program; Marley chair, neurology; professor of neurology, University of Arizona College of Medicine; and Cotara principal investigator at the Barrow Neurological Institute. "GBM is a deadly disease with very poor survival prospects for
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
2. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
3. Statement from American Water Works Association on Associated Press Story on Pharmaceuticals in Drinking Water
4. Vion Pharmaceuticals Regains NASDAQ Listing Compliance
5. NPS Pharmaceuticals to Report 2007 Financial Results
6. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
7. Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results
8. Notice of Bradmer Pharmaceuticals Conference Call
9. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
10. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter 2007 Financial Results
11. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... MIDDLEBURY, CT (PRWEB) July 11, 2014 ... announced today the launch of the Timex Performance Network, ... product information, training plans, athlete testimonials, seasonal news and ... Performance Network will capitalize on the legacy of the ... online destination for runners and endurance athletes nationwide. The ...
(Date:7/11/2014)... 11, 2014 (HealthDay News) -- Polio is history in ... like Afghanistan, Nigeria and Pakistan. Giving vaccinated children an ... immunity and help eradicate the highly infectious disease, a ... highly effective, immunity wanes as early as a year ... infected and contribute to the spread of the disease, ...
(Date:7/11/2014)... AngelWeddingDress is now providing worldwide clients with ... ”. When it comes to buying summer wedding dresses ... the unlimited stock of beautiful wedding gowns. Recently, the ... summer wedding gowns. , The company’s current promotion ... pace with the newest fashion trends. The top experts ...
(Date:7/11/2014)... Alliance Labs announced that they will be featured ... Jr, airing later this year 2014, via Discovery Channel. ... Innovations will explore DocuSol® Kids, a mini-enema containing a ... base designed to give adolescents general constipation relief. Viewers ... hyperosmotic laxative by drawing water into the bowel from ...
(Date:7/11/2014)... July 11, 2014 Anterior Cruciate Ligament ... but the type of material used to create a ... the game, say researchers presenting their work today at ... Sports Medicine ( AOSSM ). , “Our ... allografts (tissue harvested from a donor) fail more frequently ...
Breaking Medicine News(10 mins):Health News:Timex Announces Launch of Timex Performance Network 2Health News:Researchers Assess New Way to Boost Polio Immunity 2Health News:AngelWeddingDress Will Continuously Unveil More Summer Wedding Dresses for Loyal Clients 2Health News:Alliance Labs & DocuSol® to be Featured in Upcoming Episode of Innovations 2Health News:ACL Reconstructions May Last Longer With Autografts 2
... cases from two severely disabled children. These cases were mainly ... negligent medical advice. //One such is that of Alexia Harriton, ... that her family doctor had not informed her mother about ... is that of a five-year-old Keeden Waller who was born ...
... The Australian Medical Association announced today that six doctors ... the implementation of new rosters,//which they contend could harm ... doctors are simply expressing displeasure over the new working ... the resignation of the doctors was effective from this ...
... the doctors of the Royal College of Physicians it was ... //It was found that about 73% of the doctors were ... dying where it states that the doctors should be given ... the terminally ill person. But the physicians of the ...
... Office workers are at an increased risk of being affected ... hours on their computer.// DVT is a condition that gives ... the heat or the lung with often fatal consequences. ,This ... e-thrombosis. The condition came to light after it emerged that ...
... take place on June 18 has been advanced to ... the advancement but the centre is against the advancement ... the death of about 1,000 to 2,000 lives every ... children in Muslim-dominated areas are dying. About 5.2 million ...
... from Uttar Pradesh has disproved the claims of health authorities ... been reported in the state. ,This is reported ... (NPSP) issued here this month. ,Some of the ... by the state but also by international agencies like UNICEF, ...
Cached Medicine News:Health News:Fresh Polio Cases Reported In Uttar Pradesh 2
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 Shire plc ... waived the Office of Fair Trading (OFT) approval condition to the ... Incorporated (NASDAQ: VPHM).   As a result of the ... Shire expects to complete the tender offer on January 24, 2014 ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... Incorporated (NASDAQ: VPHM ) today announced the ... ILNS) to its clinical stage drug candidate, OX1, being ... rare, hereditary, progressive neurodegenerative disease. OX1, ... molecule that has potent anti-oxidant properties that can protect ...
... KIRKLAND, Wash., Sept. 29, 2011 Cardiac Dimensions®, Inc. ... Mark approval for a newly enhanced version of its ... heart failure patients suffering from functional mitral regurgitation (FMR). ... initiate a commercial launch of the enhanced device in ...
Cached Medicine Technology:ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreich's Ataxia 2ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreich's Ataxia 3ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreich's Ataxia 4Cardiac Dimensions® Receives CE Mark Approval for Enhanced CARILLON® Mitral Contour System™ 2Cardiac Dimensions® Receives CE Mark Approval for Enhanced CARILLON® Mitral Contour System™ 3
... Advanced diagnostic capabilities combined with ease of ... product in its class. Ideal for office ... complete system for Uroflowmetry, cystometry, leak point ... configurations are available which make the OM-5 ...
... with ease of use make the OM-5 ... Ideal for office or hospital-based urodynamics, the ... cystometry, leak point pressure, or urethral pressure ... make the OM-5 flexible enough to meet ...
... with ease of use make the OM-5 ... Ideal for office or hospital-based urodynamics, the ... cystometry, leak point pressure, or urethral pressure ... make the OM-5 flexible enough to meet ...
... capabilities combined with ease of use make ... its class. Ideal for office or hospital-based ... for Uroflowmetry, cystometry, leak point pressure, or ... available which make the OM-5 flexible enough ...
Medicine Products: